Subcutaneous Amivantamab Granted FDA Priority Review for R/M HNSCC
The FDA granted Priority Review to Johnson & Johnson’s supplemental BLA for subcutaneous amivantamab plus hyaluronidase-lpuj (Rybrevant Faspro) for adults with recurrent or metastatic head and neck squamous cell carcinoma. Data from OrigAMI-4 Cohort 1 (N=102) showed confirmed ORR 42% (CR 15%, PR 27%), median PFS 6.8 months, and OS 12.5 months.
How this was made
The 30-second read
Why it matters
A Priority Review designation shortens FDA review timelines and signals regulatory receptiveness, while the reported ORR, PFS, and OS provide near-term justification for label expansion expectations.
Market read
Traders can treat this as a fresh regulatory catalyst for JNJ’s oncology pipeline, with potential repricing ahead of the eventual FDA decision date.
What to watch
The article focuses on Cohort 1 of an early-phase study; broader patient populations, durability beyond current follow-up, and comparative positioning versus existing HNSCC standards remain key uncertainties.
Background
Amivantamab is an EGFR/MET-directed bispecific antibody; the sBLA seeks a subcutaneous formulation (with hyaluronidase) for recurrent or metastatic HNSCC after prior immunotherapy and platinum chemotherapy.
Ticker impact
FDA granted Priority Review for J&J’s sBLA for subcutaneous amivantamab plus hyaluronidase in recurrent or metastatic HNSCC.
Moderate positive bias for JNJ shares around FDA review milestones, with follow-through likely tied to eventual approval timing and confirmatory data.
The article discloses a new FDA regulatory action (Priority Review) plus specific efficacy/safety outcomes from a defined study cohort, which can re-rate pipeline expectations even without a final approval date.
Market effects
Reinforces momentum for EGFR/MET bispecifics and subcutaneous formulations in solid tumors, potentially lifting sentiment for similar targeted oncology programs.
Primarily US regulatory catalyst, but can influence global biotech/oncology risk appetite.
Could affect competitive positioning for head and neck cancer treatment landscapes internationally if approval follows.
Counterpoint
Priority Review is not approval; investors may discount the catalyst until confirmatory endpoints, manufacturing readiness, and final FDA decision are known.
Key entities
- companyJohnson & Johnson
Named as the sponsor/quoted party; FDA Priority Review granted for its sBLA in HNSCC.
- regulatorFDA
Granted Priority Review for the supplemental Biologics License Application.
- clinical_trialOrigAMI-4 (NCT06385080)
Open-label phase 1b/2 study providing Cohort 1 efficacy and safety data supporting the sBLA.
